MétaCan
Menu
Back to cohort
Record W2597395605 · doi:10.1016/s0167-8140(15)41040-0

PO-1048: HDR brachytherapy combined to EBRT for prostate cancer: analysis of toxicities and PSA bounce of a phase II trial

2015· article· en· W2597395605 on OpenAlexaff
Audrey Tétreault-Laflamme, Thu Van Nguyen, F. Vincent, Fred Saad, Nicolas Benoît, B. Fortin, Carole Lambert, M. Jolicoeur

Bibliographic record

VenueRadiotherapy and Oncology · 2015
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Diagnosis and Treatment
Canadian institutionsHôpital Maisonneuve-RosemontCentre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-QuébecHôpital Charles-Le MoyneCentre Hospitalier de l’Université de Montréal
Fundersnot available
KeywordsBrachytherapyMedicineProstate cancerOncologyUrologyCancerInternal medicineRadiation therapy

Abstract

fetched live from OpenAlex

Purpose/Objective: To assess acute and late toxicities and report the frequency and timing of the PSA bounce in intermediate-risk prostate cancer patients treated with brachytherapy and hypofractionated external beam radiotherapy (EBRT) combined with short course androgen deprivation therapy (ADT).Materials and Methods: Between August 2003 and September 2007, 51 patients with intermediate-risk prostate cancer were enrolled in a dose escalation phase II protocol (BRP-1 trial).The treatment regimen applied was as followed: patients received six months of ADT (three months neoadjuvantly and three months concurrently) and underwent high-dose-rate (HDR) Ir 192 prostate brachytherapy, for a prescribed dose of 19.5Gy (three fractions of 6.5Gy each); followed one week later, by hypofractionated EBRT at a dose of 50Gy in 20 fractions.Patients were assessed one month post-treatment, every three to six months for the first five years and annually thereafter.APS, testosterone and complete blood count were taken on each visit.Gastrointestinal (GI), genitourinary (GU) and sexual toxicities were assessed according to the RTOG toxicity scoring criteria.Patients also completed the Expanded Prostate Cancer Index Composite (EPIC) questionnaires for quality of life every 6 months.Results: Median age was 68.5 years (range 51-83 years).At diagnosis, 31.8% of patients had grade 2 or higher for GU symptoms according to the RTOG scoring criteria, no one had grade 2 GI symptoms and 50% had grade 2 or higher erectile dysfunction.Median follow-up was 80 months (range 4.9-132 months).Rates of grade 2 and higher GU toxicity at 1, 12 and 60 months were 33.8%, 12.8% and 23.5%, respectively.No grade 2 or higher GI toxicities were reported at 1 and 12 months and a rate of 5.9% was observed at 60 months.Grade 2 and 3 erectile dysfunction at 1, 12 and 60 months was reported in 2.1%, 19.2% and 16.1% and 91.7%, 57.2% and 71% of patients respectively.No grade 4 toxicity was reported.PSA bounce was observed in 33.3% of patients at a median of 12 months (range 3-42 months) and the median time to PSA normalization was 18 months (range 3-24 months).Conclusions: Acute and late GU and GI toxicities were acceptable for patients with intermediate-risk prostate cancer treated with HDR brachytherapy and hypofractionated EBRT combined to short course ADT.Rates of erectile dysfunction were probably affected by the use of a short course of ADT.PSA bounces are common, and occur up to 42 months in our cohort.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.021

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.002
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0030.003
Bibliometrics0.0010.001
Science and technology studies0.0000.002
Scholarly communication0.0020.001
Open science0.0020.001
Research integrity0.0020.005
Insufficient payload (model declined to judge)0.0060.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.038
GPT teacher head0.378
Teacher spread0.340 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2015
Admission routes1
Has abstractno

Explore more

Same venueRadiotherapy and OncologySame topicProstate Cancer Diagnosis and TreatmentFrench-language works237,207